Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
23.74
Nov 06 • 3:59 PM ET Dollar change+5.08 Percentage change(27.22%)
Aftermarket Close
23.50
Aftermarket • 7:30 PM ET Dollar change-0.24 Percentage change(-1.01%)
Nov 06, 8:31 PMQ3 EPS beat and billing-fix margin rebound lift Fulgent Genetics 27%
Index
RUT
Market Cap
663.27M
Enterprise Value
375.12M
Income
-90.93M
Sales
330.27M
Book/sh
35.68
Cash/sh
10.48
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
1344
IPO
Sep 29, 2016
P/E
-
Forward P/E
-
PEG
-
P/S
2.01
P/B
0.67
P/C
2.27
P/FCF
-
EV/EBITDA
-
EV/Sales
1.14
Quick Ratio
5.33
Current Ratio
5.34
Debt/Eq
0.01
LT Debt/Eq
0.01
Option/Short
Yes / Yes
EPS (ttm)
-3.09
EPS next Y
-1.38
EPS next Q
-0.69
EPS this Y
-640.48%
EPS next Y
39.21%
EPS next 5Y
-
EPS past 3/5Y
- -
Sales past 3/5Y
-19.52% -5.21%
EPS Y/Y TTM
-120.44%
Sales Y/Y TTM
4.67%
EPS Q/Q
-121.22%
Sales Q/Q
7.54%
Insider Own
36.00%
Insider Trans
-0.12%
Inst Own
56.95%
Inst Trans
-10.90%
ROA
-7.93%
ROE
-8.59%
ROIC
-9.11%
Gross Margin
31.05%
Oper. Margin
-37.55%
Profit Margin
-27.53%
SMA20
15.57%
SMA50
14.12%
SMA200
23.82%
Trades
Shs Outstand
27.76M
Shs Float
17.61M
52W High
31.04 -23.52%
52W Low
13.46 76.37%
Volatility
8.73% 4.97%
ATR (14)
1.17
RSI (14)
64.32
Beta
1.04
Rel Volume
3.88
Avg Volume
283.13K
Volume
1,097,588
Perf Week
15.13%
Perf Month
14.02%
Perf Quarter
24.55%
Perf Half Y
48.75%
Perf YTD
-9.63%
Perf Year
6.41%
Perf 3Y
-12.50%
Perf 5Y
-69.29%
Perf 10Y
171.62%
Prev Close
18.66
Price
23.74
Change %
27.22%
Consensus
Hold
Avg. Price Target
$19.00
Implied Upside
-20.0%
Analysts7incl. previous ratings
Rating Distribution5 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Aug 05, 2025Upgrade
UBS logoUUBS
Neutral → Buy$30+26.4%
Dec 07, 2023Initiated
UBS logoUUBS
Neutral$35+47.4%
Dec 08, 2022Downgrade
PPiper Sandler
Overweight → Neutral$65 → $40+68.5%
Nov 18, 2022Initiated
RJF logoRRaymond James
Outperform$45+89.6%
Aug 25, 2022Initiated
CCredit Suisse
Outperform$65+173.8%
Feb 04, 2022Resumed
PPiper Sandler
Overweight$80+237.0%
Aug 05, 2021Resumed
CCredit Suisse
Underperform$55+131.7%
Jan 08, 2021Downgrade
CCredit Suisse
Neutral → Underperform$42 → $40+68.5%
Nov 24, 2020Downgrade
BBTIG Research
Buy → Neutral
Aug 20, 2020Initiated
OPY logoOOppenheimer
Outperform$75+215.9%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gao HanlinChief Scientific OfficerSep 02 '26Sale19.661,67332,885986,117Sep 03 07:47 PM
Xie JianPresident and COOSep 02 '26Sale19.662,12741,809359,924Sep 03 07:47 PM
Xie Jian OfficerSep 02 '26Proposed Sale19.662,12741,809Sep 02 08:42 PM
Gao Hanlin OfficerSep 02 '26Proposed Sale19.661,67332,885Sep 02 08:42 PM
Xie JianPresident and COOAug 27 '26Sale19.911,19323,747362,051Aug 28 06:06 PM
Gao HanlinChief Scientific OfficerAug 27 '26Sale19.9193918,691987,790Aug 28 06:05 PM
Gao Hanlin OfficerAug 27 '26Proposed Sale19.9193918,691Aug 27 08:33 PM
Xie Jian OfficerAug 27 '26Proposed Sale19.911,19323,747Aug 27 08:31 PM
Xie JianPresident and COOJun 02 '26Sale17.892,14638,382367,605Jun 03 05:29 PM
Gao HanlinChief Scientific OfficerJun 02 '26Sale17.891,68830,191990,374Jun 03 05:29 PM
Xie Jian OfficerJun 02 '26Proposed Sale17.892,14638,382Jun 02 08:31 PM
Xie JianPresident and COOMay 27 '26Sale17.601,20121,138369,751May 28 05:22 PM
Gao HanlinChief Scientific OfficerMay 27 '26Sale17.6094516,632992,062May 28 05:19 PM
Xie JianPresident and COODec 02 '25Sale28.331,14032,298336,749Dec 03 05:04 PM
Gao HanlinChief Scientific OfficerDec 02 '25Sale28.331,07530,457952,890Dec 03 05:04 PM
Xie JianPresident and COONov 28 '25Sale29.571,19835,424337,889Dec 01 09:14 PM
Gao HanlinChief Scientific OfficerNov 28 '25Sale29.5794327,884953,965Dec 01 09:14 PM
Gao Hanlin OfficerDec 02 '25Proposed Sale28.521,07030,516Dec 01 09:13 PM
Xie Jian OfficerDec 02 '25Proposed Sale28.521,13532,370Dec 01 09:12 PM
Xie Jian OfficerNov 28 '25Proposed Sale30.151,19836,120Nov 26 08:26 PM
Gao Hanlin OfficerNov 28 '25Proposed Sale30.1594328,431Nov 26 08:24 PM
Xie JianPresident and COONov 24 '25Sale30.4768120,752339,087Nov 25 04:30 PM
Gao HanlinChief Scientific OfficerNov 24 '25Sale30.4753516,303954,908Nov 25 04:30 PM
Xie Jian OfficerNov 24 '25Proposed Sale30.4768120,752Nov 24 06:37 PM
Gao Hanlin OfficerNov 24 '25Proposed Sale30.4753516,303Nov 24 06:36 PM
Xie JianPresident and COONov 19 '25Sale29.1010,000290,983349,768Nov 21 04:30 PM
Xie Jian OfficerNov 19 '25Proposed Sale29.1010,000290,983Nov 19 08:03 PM
Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded by Ming Hsieh on May 13, 2016 and is headquartered in El Monte, CA.
Chairman & CEOMr. Ming Hsieh
COO & PresidentMr. Jian Xie
Chief Financial OfficerMr. Paul Kim CPA
FACMGDr. Hanlin Gao D.A.B.M.G.
CIPPMs. Natalie Prescott CIPM